Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 7/20 | 0.42 |
| ▸ | FLT1 | P17948 | 6/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | CIT | O14578 | 1/20 | 0.41 |
| ▸ | HLA-A | P04439 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | FRK | P42685 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203187 | 0.75 | NPC1 (0.46) | CSNK2A1CSNK2BCSNK2A2PIM1PIM2 | |
| SCHEMBL6496240 | 0.75 | KDR (0.58) | KDRFLT1EGFRCITHLA-A | |
| SCHEMBL30413717 | 0.74 | DYRK1A (0.47) | PIM1KDRCSF1RRETPDGFRB | |
| SCHEMBL2201586 | 0.74 | DYRK1A (0.47) | PIM1KDRCSF1RRETPDGFRB | |
| Hydrochloric Acid SCHEMBL6502127 | 0.73 | KDR (0.57) | KDRFLT1EGFRCITHLA-A | |
| SCHEMBL2197122 | 0.73 | FLT1 (0.50) | CSNK2A1CSNK2BPIM1PIM2KDR | |
| SCHEMBL12233349 | 0.70 | KDR (0.47) | KDRFLT1EGFRCITHLA-A | |
| SCHEMBL31751683 | 0.68 | DYRK1A (0.55) | PIM1KDRCSF1RRETPDGFRB | |
| SCHEMBL10132467 | 0.68 | CSNK2A1 (1.00) | CSNK2A1 | |
| SCHEMBL12233317 | 0.67 | AURKA (0.47) | KDRFLT1EGFRCITHLA-A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | disclosed |
| CN-100374435-C | Substituted pyridazines having angiogenesis inhibiting activity | BAYER CORP (US) | 2008-03-12 | — | — | CN | disclosed |
| WO-2007118602-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118602-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2007-10-25 | — | — | WO | disclosed |
| CN-1769282-A | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORP (US) | 2006-05-10 | — | — | CN | disclosed |
| CN-1769283-A | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORP (US) | 2006-05-10 | — | — | CN | disclosed |
| US-20040092740-A1 | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-6689883-B1 | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORPORATION | 2004-02-10 | — | — | US | disclosed |
| CN-1420879-A | Substituted pyridines and pyridazines having angiogenesis inhibiting activity | BAYER AG (US) | 2003-05-28 | — | — | CN | disclosed |
| EP-1228063-A2 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Corporation (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001023375-A2 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092740-A1 | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | VEGFA, PGF, FLT1 | CSNK2A1 1010/4885CSNK2B 937/4885CSNK2A2 1326/4885 |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | VEGFA, PGF, FLT1 | CSNK2A1 1946/4885CSNK2B 1357/4885CSNK2A2 2088/4885 |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | PTGIR, PTGIS, EDNRB | CSNK2A1 2534/4885CSNK2B 2446/4885CSNK2A2 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.